Background and Aims: Patients with inflammatory bowel diseases are prone to cutaneous manifestations. The aim of this study was to investigate their prevalence, type and association to demographic and clinical factors. Methods: This was a cross-sectional study. Information relative to patients of a central Portuguese hospital with a definitive diagnosis of an inflammatory bowel disease, who were prospectively recruited, was collected. Results: The final cohort included 342 patients, 62% of whom had Crohn's disease and 38% had ulcerative colitis. Cutaneous extraintestinal manifestations were present in 44.4% of all patients; this prevalence was lower [14.9%] , p = 0.004). Additionally, their occurrence was related to patients up to 16 years ], p = 0.028) among the Crohn's disease sub-cohort, whereas in the ulcerative colitis sub-cohort they were more likely to occur in patients with extensive colitis , p = 0.008). Conclusions: Nearly half of the patients analysed had at least one cutaneous extraintestinal manifestation. The fact that certain lesions tend to be more common among patients with defined characteristics should alert the physicians and allow an early diagnosis and, when pertinent, a reference to dermatology.
Introduction
Inflammatory bowel diseases [IBD] , which include ulcerative colitis [UC] and Crohn's disease [CD] , are immunity-driven auto-inflammatory disorders with potential systemic involvement and a complex clinical presentation. 1 Extraintestinal manifestations [EIM] are known to be prevalent among IBD patients and may involve different organs and systems. The most common EIM have a musculoskeletal or dermatological nature, followed by those that affect the ocular, hepatobiliary or endocrinological systems. [2] [3] [4] Their clinical spectrum varies from mild and transitory to severe, and they can sometimes be more incapacitating than the intestinal symptomatology itself. 1, 5 The incidence of cutaneous EIM [cEIM] among IBD patients varies across the literature according to the definition used in each study. 2, 4 Globally, about one-third of patients with IBD are expected to develop EIM, and from these up to one-third will have cEIM. 6, 7 The cumulative probability of patients with IBD having at least one EIM was reported to increase from about 12 to 30% during a 20-year follow-up period. 8 From 4.5 to 25% of IBD patients have more than one EIM, and the development of one EIM apparently increases the risk of developing further ones, which suggests the existence of common pathogenic pathways underlying onset of different EIM. [3] [4] [5] 9, 10 Environmental [smoking] and genetic factors [NOD2/CARD15 mutations, HLA-B8/DR3, HLA-DRB1*0103, HLA-B27 or HLA-B58 phenotypes] have been implicated in the pathogenesis of EIM. 3, 11 In the particular case of cEIM, recent studies have related several TRAF3IP2 gene variants with an increased risk of developing skin lesions, suggesting that sequencing TRAF3IP2 in IBD patients may be helpful for the identification of those who have a higher propensity for this kind of EIM. 12 This study aimed to evaluate the prevalence and type of cEIM in a cohort of IBD patients, as well as to determine the association between those manifestations and IBD patients' demographic and clinical factors. The recruited patients were clinically evaluated by a gastroenterologist [FM] and two dermatologists [FO and SM] . Patients' information on past and present cEIM was collected. Lesions described in the patients' clinical history but detected before IBD diagnosis were not considered in this analysis. Skin biopsies were performed whenever considered helpful. The appropriate therapy[ies] were prescribed by the dermatologists and, whenever pertinent, the patients were evaluated at a subsequent dermatology appointment. Cutaneous EIM were diagnosed by the dermatologist and categorized into the five major groups depicted in Table 1 . Group 1 includes granulomatous lesions, which have the same histological features as the underlying bowel disease and therefore result from the same histopathological processes [perianal disease was excluded]; group 2 includes lesions that are reactive to the underlying IBD, resulting from immunological mechanisms triggered by gut and skin bacteria common antigens; group 3 includes immunologically associated lesions, which are probably related to human leukocyte antigen [HLA] linkage, chronic inflammatory IBD pathogenic pathways or anti-TNF therapy; group 4 includes lesions that are secondary to nutritional deficiencies, resulting from impaired absorption, increased nutritional requirements and poor dietary intake, or inadequate supplementation in total parenteral nutrition; and group 5 includes lesions that occur in response to IBD pharmacological and/or surgical treatments [anti-TNF-induced lesions were included in group 3 due to their immunological nature].
Material and methods

Patients and study design
Variables
Statistical analysis
Categorical variables were described as absolute frequencies [n] and relative frequencies [%] . Mean and standard deviation or median and interquartile range [IQR] were used for continuous variables. When testing an hypothesis about continuous variables, the t-test was applied, taking into account normality assumptions and the number of groups compared. When testing an hypothesis about categorical variables, the chi-square test and Fisher's exact test were used, as appropriate. To have a more thorough understanding of the factors associated with the cEIM, univariate and multivariate logistic regression models were used. Controls were defined as IBD patients of the study not having the specific cutaneous lesion under analysis. The significance level used was 0.05. Statistical analyses were performed using the software Statistical Package for the Social Sciences v. 24.0.
Literature review
An exhaustive literature review was conducted in the PubMed database, using the search terms 'inflammatory bowel disease and cutaneous extraintestinal manifestations', with no date of publication or language filter. Reviews, meta-analysis, case-control and cohort studies were included. References from prior pertinent articles were also searched to identify studies of interest that may have been missed by the above-mentioned search. Studies reporting duplicate data were excluded.
Ethical statement
This study was carried out in accordance with the Declaration of Helsinki. Data were collected from the GEDII database, approved by the National Data Protection Commission. Subjects gave informed consent to use their clinical data for this study. 
Results
Cohort characterization and lesion classification
Granulomatous lesions
Metastatic CD was found in one patient [0.3%], in the form of cheilitis granulomatosa [ Figure 1 ]. Perianal lesions were found in 53 patients [15.5%] ; however, and according to the criteria described in the Material and methods section, these lesions were considered an extension of the IBD itself rather than cEIM.
Reactive cutaneous lesions
Reactive skin manifestations were diagnosed in 15 patients Table 2 ].
EN was reported in female patients only [p = 0.007] [see Supplementary Table S1 ], of whom two had UC and six had CD. Among CD patients with EN, four had colonic involvement and two had isolated small bowel disease. PG was present in two male patients [one had CD and one had UC] and two female patients [one had CD and one had UC], and colonic involvement was reported for both CD patients. Aphthous stomatitis was observed in one male patient and one female patient, both with CD. The single case of SS was reported in a male patient with extensive UC.
Immunologically associated lesions
Immunologically associated dermatoses were found in 36 patients [10.5%]. The majority [24 patients, 7 .0%] had psoriasis [ Figure 3a, 20 Erythema nodosum 20, 27 Leukocytoclastic vasculitis 20 Necrotizing vasculitis 6 Polyarteritis nodosa 6, 21 Pyoderma gangrenosum 20, 27 Pyoderma vegetans 20 Pyoderma-Pyostomatittis vegetans 20 Pyostomatittis vegetans 20 Recurrent aphthous stomatitis 21 Sweet's syndrome 20, 27 Vesiculopustular eruptions 6, 45 Immunologically associated Acquired epidermolysis bullosa 20 Actinic keratosis 36 Bullous pemphigoid 20 Dermatitis herpetiformis 45 Erythema multiforme 45 Finger clubbing 31 Hidradenitis suppurativa 41 Lichen planus 45 Lupus erythematosus Figure 3a ,b], whereas from the 17 who displayed psoriasis and were not medicated with anti-TNF agents, 15 had the typical plaque-type and only two had palmoplantar and/or scalp involvement [11.1% vs 0.3%, p < 0.001]. In addition, scalp psoriasis in those medicated with anti-TNF agents led to alopecia in two patients.
Nutritionally related lesions
Only two types of nutritionally related cEIM were reported in this cohort: 21 patients had xerotic eczema [6.1%] [ Figure 4a ], whereas a single patient had angular cheilitis [0.3%] [ Figure 4b ].
Therapy-related lesions
Infections were the main kind of dermatoses secondary to treatment reported in this study. Fifty-seven patients [16 
Discussion
Clarification and standardization of the cEIM classification is crucial to compare studies and to provide better understanding of these complications. Overall, we have detected a cEIM prevalence of 44.4% among IBD patients, which is within the range of that found in the literature [2-53%]. [2] [3] [4] [7] [8] [9] [14] [15] [16] [17] [18] [19] The width of this range shows that the accurate determination of cEIM might be a complex issue, and can be explained by the utilization of different classification systems, as well as different inclusion/exclusion and diagnostic criteria. 6, 20, 21 The major differences seen in the literature are related to the inclusion or exclusion of perianal disease and indirect dermatoses, related to nutritional deficiencies or treatments. Moreover, the definition of the immunologically associated category can be heterogeneous, as some dermatoses [e.g. psoriasis] may be considered either as separate entities [in which case they tend to show an IBDindependent course] or as a response to treatments, namely anti-TNF drugs. Other sources of variation are the study design [prospectively vs retrospectively recruited cohorts] and the specialization of the physician reporting the lesions [dermatology, gastroenterology or general practice]. 21 Regarding the association between cEIM and demographic-, clinical-and patient-related factors, our results were similar to those previously reported. 2, 22 In general, cEIM excluding those secondary to treatments or nutritional deficiency were more frequently found in females and younger patients. Likewise, they were associated with CD patients who were diagnosed before the age of 40 years [Montreal A1 and A2]. In UC, disease location was also shown to be a significant factor, with patients with extensive colitis presenting a higher prevalence of cEIM. The literature also suggests that skin disorders are more frequent among CD patients with colonic involvement; however, no effect of disease location could be discerned among CD patients of this cohort. 7, 21 Reactive skin eruptions, namely EN and PG, are one of the most frequently reported cEIM, and are therefore the most well-studied category. In our study, as well as in the literature, these lesions are significantly more frequent in women, younger patients and in those with active IBD disease. 2, 6, 22 The prevalence of EN varies widely in the literature, affecting 1-10% of IBD patients. 7, [14] [15] [16] [17] [18] 20, [22] [23] [24] [25] [26] Overall, these lesions seem to be more common in CD than in UC patients, having a prevalence of 4-15% and 3-10% [respectively]. 5, 14, 18, 20, 22, 24, 27, 28 Moreover, EN seems to be associated with colonic involvement in CD. 7, 8, 20, 24, 29 In our study, the global prevalence of EN was 2.3% [2.8% among CD patients and 1.5% among UC patients] with no significant difference concerning the IBD type. EN depends on IBD activity, and hence is often self-limited and improves with the IBD treatment. Therefore, the presence of EN in patients considered to be in remission regarding their IBD should prompt physicians to further investigate gastrointestinal disease activity, even in the absence of symptoms. First-line EN treatment includes controlling underlying IBD activity, leg elevation, bed rest and non-steroid anti-inflammatory drugs. In severe cases, a short period of systemic corticosteroids [0.5-1 mg/kg/day] may be necessary. 30 PG, in turn, can be found in 0.6-2.2% of IBD patients, and 20-30% of PG cases occur in IBD patients. 1, 7, [14] [15] [16] [17] [18] 21, 22, [24] [25] [26] 28 Some studies have shown a higher prevalence of PG in UC [when compared to CD], 7, 21 whereas others fail to show such a trend. 5, 8, 14, 23, 31 The relationship between disease location in CD patients and PG manifestations is dubious: a few studies point towards an association between PG and colonic involvement, 20, 24, 27 but at least one study failed to corroborate this. 14 In our study, the prevalence of PG was 1.5% among UC patients and 0.9% among CD patients. This difference is not significant, which is not surprising given the overall low prevalence of PG in this cohort. However, note that all CD patients with PG manifestations [two] have colonic involvement. As in EN, if underlying IBD is active and PG seems to be parallel, IBD should be treated first. Concerning treatment, mild PG forms might respond to local therapy with corticosteroids [topical or intralesional]. However, in most cases, systemic immunosuppression is required [corticosteroids, cyclosporine or anti-TNF drugs]. 32 Psoriasis has been reported as the most frequently observed immunologically associated cEIM in IBD patients. 33 Interestingly, these lesions may appear at the onset of IBD or later in its development, as a response to the anti-TNF therapy. Whereas its prevalence in the general population ranges between 1 and 2%, its prevalence among IBD patients varies across different studies, within the range 7-11% 7, 20, 33, 34 or 0.5-2%. 9, 15, 18, 25, 35 Moreover, psoriasis seems to be more frequent in women and in patients with CD, 36 while its association with age is not consensual. 35, 36 Our results do not support the higher prevalence of psoriasis among CD patients, although they reveal an association with female gender, younger age and anti-TNF treatment, especially with infliximab. Whether this last increased risk is due solely to the anti-TNF therapy itself or has a histopathological basis remains to be established. Patients medicated with anti-TNF drugs displayed pustular lesions with a higher degree of inflammation compared with non-medicated patients, and in the former palmoplantar and scalp psoriasis were the most frequent types of psoriasis observed, as has been described in the literature. 37 First-line treatments for psoriasis include topical agents such as betamethasone and vitamin D analogues and ultraviolet phototherapy. In moderate to severe cases, with or without articular involvement, systemic immunosuppression may be necessary [methotrexate, acitretin, cyclosporine and biological agents]. 38 Regarding the association of paradoxical psoriasis with anti-TNF treatment, two recent studies should be highlighted: these reports support that the occurrence of anti-TNF-related dermatological complications, such as psoriasis, but do not necessarily imply cessation of therapy, as most cases can be successfully addressed using topical treatments and ultraviolet phototherapy. Although some patients may respond to conservative therapeutic measures, anti-TNF suspension should be considered, particularly if such a response is not observed. [36] [37] [38] [39] [40] Those patients should be followed in parallel by a gastroenterologist and a dermatologist.
A higher risk for hidradenitis suppurativa [HS] in IBD patients is well established in the literature. HS should not be misdiagnosed as metastatic CD [genital or extragenital]. 41 HS prevalence varies from 1.2 to 23% among IBD patients, being higher in CD than in UC patients. 42 The relative risk of HS among IBD patients has been shown to be approximately nine times higher when compared with that of the general population. 43 A possible reason for the low prevalence of HS in our cohort [0.6%] is the potential simultaneous treatment of the IBD and HS with anti-TNF agents, as has been described before. 44 Regarding nutrition-related skin lesions, the low prevalence of angular cheilitis observed [only one patient] may be justified by the fact that all iron-deficient patients were receiving supplementation.
The prolonged use of immunosuppressive therapies is known to increase the risk of adverse drug reactions, including those of a dermatological nature. Several studies consider dermatoses secondary to treatment as cEIM, 6, 20, 21, 27 although there is not yet a consensus on this matter. [2] [3] [4] 27 However, whereas it may be difficult to discern whether certain common skin disorders are secondary to treatment, infections have definitely been associated with immunosuppression. Our results thus show that the simultaneous treatment with an anti-TNF and azathioprine increases the likelihood of suffering a skin infection. Those taking azathioprine were more prone to human papilomavirus and herpes zoster manifestations.
The present study has some limitations: all patients were recruited from a single hospital; and some of the lesions were retrospectively collected from patients' clinical histories, which may be prone to bias. However, one of the study's strengths is that all lesions were evaluated in the presence of a dermatologist, which allowed a rigorous and thorough classification.
In summary, nearly half of the patients analysed had at least one cEIM. It was noteworthy that these lesions are particularly prevalent among women and young patients. It is therefore important to be aware of the association of specific skin lesions with IBD. Good communication between the gastroenterologist and the dermatologist may help to diagnose, manage and reduce cutaneous morbidity among IBD patients.
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